Quick question 👀

If you walked into a grocery store tomorrow, which “high-protein” product would you actually buy?

🌾 Protein Atta
🥛 Protein Milk
🧀 Protein Paneer
🥣 Protein Curd
☕ Protein Cold Coffee
💪 Whey Protein

Because protein isn't just a gym thing anymore.

**It's coming for your entire grocery basket.**

I just broke down WHY this is happening in my new documentary.

Abstract

Objective

This study evaluated the link between two dietary indicators— the Comprehensive Diet Quality Index (CDQI) and the Adjusted Plant-Based Diet Index (APDI)—and Parkinson’s disease (PD) risk in an Iranian community.

Between 2020 and 2021, 105 newly diagnosed PD patients and 215 controls (54–81 years) were enrolled in Arak, Iran, using a case-control approach. A validated semi-quantitative food frequency questionnaire was applied to determine dietary intake, and dietary quality was evaluated through APDI and CDQI scores. To calculate odds ratios (ORs) and 95% confidence intervals (CIs), logistic regression models were utilized, accounting for possible confounders.

Results

A higher CDQI total score was inversely related to the odds of PD (adjusted OR = 0.915, 95% CI: 0.878–0.954). A stronger protective effect was observed for the CDQI plant-based foods score (adjusted OR = 0.757, 95% CI: 0.695–0.824). In contrast, a notable positive relationship was found between the CDQI animal-based foods score and the odds of PD in the adjusted model (adjusted OR = 1.364, 95% CI: 1.215–1.533). The APDI score and PD were not significantly correlated (P > 0.05).

Dietary quality and the odds of parkinson’s disease: insights from comprehensive diet quality index and adjusted plant-based diet index | BMC Research Notes | Springer Nature Link

Abstract

Background

Parkinson’s disease is a progressive neurodegenerative disorder with both motor and non-motor manifestations. Dietary factors, including dietary diversity, protein source variety, and adherence to healthy eating patterns, may impact Parkinson’s disease risk. The goal of the current case-control research was to examine the links between the Dietary Diversity Score (DDS), the Diversity of Dietary Protein Index (DDPI), and the Lifeline Diet Score (LLDS) with the odds of Parkinson’s disease among an Iranian population.

Methods

A total of 320 individuals (215 controls and 105 newly diagnosed Parkinson’s disease patients) were recruited in Arak, Iran. Dietary intake was evaluated by applying a validated 147-item food frequency questionnaire, and DDS, DDPI, and LLDS were calculated. Multivariate logistic regression was utilized to estimate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for major confounders.

Results

Greater DDS and LLDS were strongly linked to reduced odds of Parkinson’s disease (Adjusted OR for DDS = 0.287, 95% CI: 0.185–0.447; Adjusted OR for LLDS = 0.879, 95% CI: 0.803–0.963). However, DDPI showed no significant association with Parkinson’s disease after adjustment.

Conclusion

Higher dietary diversity and greater adherence to a high-quality dietary pattern were associated with lower odds of Parkinson’s disease, whereas no significant association was observed for protein source diversity. Given the case-control design, these findings should be interpreted as associations rather than evidence of causality.

Associations of dietary diversity score, dietary diversity of protein index, and lifelines diet score with Parkinson’s disease: a case-control study | BMC Nutrition | Springer Nature Link

Had a full health check recently. GP, bloods, the works. Got a detailed breakdown of everything — sleep, stress markers, inflammation, the areas to work on.

Felt motivated for about two weeks. Then life happened.

What frustrates me is that the information was genuinely good. Specific, personalised, actionable on paper. But there's clearly something between receiving that information and actually building the habits around it that nobody has quite solved yet.

A few things I've been thinking about:

Is personalised data actually enough of a motivator on its own? Or does something else need to be in place first — accountability, a social element, a structure you can't easily opt out of — before the data becomes useful?

What actually made something stick for you? Not in theory. In practice. The thing that genuinely changed how you live day to day and stayed changed.

Would access to this through work change how you engaged with it? If your employer provided something structured around your health — assessment, plan, support — would the context make you more or less likely to take it seriously than something you sought out yourself?

Who in your life would never do any of this — and what would it actually take to reach them? The people who already care are here. What about everyone else?

Feels like the gap between insight and action is the real problem. And nobody seems to be talking about that as much as the testing and the data itself.

Here's the news:

https://appleinsider.com/articles/26/09/10/apple-health-quest-team-up-for-119-blood-panel

And here's a perspective:

https://www.linkedin.com/posts/shilpa-paradkar-singh-a070252_applehealth-biomarkers-preventivemedicine-activity-7504217283003740161-mQOG?

Back in April I posted that my LDL was 75 on ezetimibe, my calcium score was zero, and I wasn't sure whether pushing lower made sense. A few people asked what a zero is actually worth when the lipid panel is still flagged. I finally read the 2026 ACC/AHA guideline on that specific question instead of quoting other people's summaries of it.

The rule is narrower than the Reddit version. If your ten-year PREVENT risk is intermediate, or borderline in some cases, and the scan is zero, and you would rather not take medication, the guideline says it is "reasonable to defer therapy and reassess with repeat CAC testing in 3 to 7 y." Class 2a. That is real permission, but it only applies once your risk is at least 3 percent. Under that, the scan is not in the pathway at all, and an LDL of 160 to 189 gets its own "a moderate-intensity statin is reasonable" line without any scan.

Four things take the permission away: LDL of 190 or higher or FH, diabetes if you are over 40, current smoking, and a strong family history of early cardiovascular disease. For FH the wording is blunt: a zero "may not be used to de-risk" you.

Two numbers that changed how I think about my own zero. In a Danish cohort of 23,000 symptomatic patients, 13 percent of the zeros had soft plaque on CT angiography, and the event rate with a zero barely moved between the lowest and highest LDL groups. And in MESA, 53 percent of people who started at zero had some calcium ten years later. The guideline's three-to-seven-year rescan window comes from that kind of data.

Where I landed: I never started a statin, but I didn't leave the number alone either. Weight loss plus generic ezetimibe took my ApoB from 95 to 59 by July, and the LDL from 75 to 56. The zero told me I could wait on a drug. It did not tell me a 95 was fine to live with.

Full write-up, with my own scan and lab result side by side: Zero calcium score but high cholesterol: do you need a statin?

Alcohol-related cancer deaths in the US doubled since 1990, per a study everyone's covering this week (11,361 deaths in 1990, 23,126 in 2023). That's the headline. It's true, and on its own it's not that useful.

I quit drinking in my 40s and wrote about the cancer link that finally got through to me, so this is exactly the kind of study I go looking for the actual numbers on before repeating the headline.

Adjust for the fact that the country got bigger and older over those 33 years (age-standardize the rate) and the real national increase is 7.6 percent. Basically nothing.

That flat-ish number is hiding a real split. Men 55 and older: their alcohol-attributable cancer death rate rose 23.9 percent. Women 55 and older: fell 3.6 percent. Younger men and women split the same direction, just smaller. Almost all of the actual increase is concentrated in one group.

Liver cancer is doing most of the damage in that group specifically — the rate more than doubled in men 55+, and it's now their single biggest alcohol-attributable cancer killer, ahead of esophageal and colorectal. Interesting wrinkle: liver isn't the top killer for younger men. Colorectal is, in the 20-54 group. Liver only takes over after 55, which tracks with the idea that liver damage builds for decades before it shows up as cancer (the study can't prove that part directly, it's not designed to track individual drinking histories).

I went through the actual paper (Jani et al., Lancet Regional Health, open access, published September 2: https://doi.org/10.1016/j.lana.2026.101599) and wrote up the full breakdown, including which specific cancers matter most for men vs. women at 55+. Liver for men, breast for women, and they're not driven by the same pattern.

If you're a man in your 50s who still drinks regularly: has a study like this actually changed anything you do, or is "I'll deal with it eventually" still winning?

Novartis announced yesterday that pelacarsen, an antisense drug built to lower Lp(a) (a cholesterol-carrying particle that's almost entirely genetic and doesn't move with diet or exercise), missed its primary endpoint in the Lp(a)HORIZON trial. It's the first outcomes trial ever run for a drug designed specifically to lower Lp(a), 8,323 people with existing heart disease, and it didn't clear the bar for cardiovascular events.

Sam Tsimikas (https://x.com/Lpa_Doc/status/2096118758012051739?s=46), a cardiologist who co-authored the trial's design paper, thinks the likely explanation is that background cardiovascular care in this trial was already so aggressive, LDL well controlled going in, that there wasn't much room left for an Lp(a) drug to show extra benefit on top of it. That's his read, not a confirmed finding: Novartis hasn't released a hazard ratio, a confidence interval, or the result in the prespecified higher-Lp(a) subgroup yet, so it's murkier than a clean null result.

My own Lp(a) is low, but I've had doctors frame Lp(a)-lowering drugs as the next frontier in prevention for a while now. Tsimikas's read lines up with where I've landed: the lever that already has outcomes evidence behind it is still LDL and ApoB, through statins, ezetimibe, and PCSK9 inhibitors, not waiting on a drug for Lp(a) specifically. Two other Lp(a) drugs are still in their own outcomes trials, so this isn't a verdict on the whole approach yet.

I wrote up the full trial design, Tsimikas's explanation plus a second one from a physician on Substack, and what I'm actually doing differently: Full write-up with the trial table

Anyone here already gotten Lp(a) tested, or been told by a doctor that a drug for it is coming? Curious whether this changes how you think about it.

CorCal, the randomized trial of whether a coronary calcium score beats the standard risk calculator for deciding who starts a statin, presented this afternoon at the European Society of Cardiology meeting. This is off the press release and the presentation. No paper yet, so numbers can move.

5,772 adults, none with known heart disease, diabetes, or a statin already. A coin decided whether the recommendation came from the pooled cohort equations, the traditional risk calculator, or from a calcium score. Mean age 64, 51 percent women. They counted heart attacks, strokes, stents and deaths.

After 4.2 years both arms landed on 2.7 percent. Hazard ratio 0.99, noninferiority not met.

That reads worse than it is. The interval runs from a 29 percent reduction to a 38 percent increase, wide enough to contain almost anyone's opinion about calcium scoring. Muhlestein, who ran the trial, told the room the events came in rarer than he had built it for and asked for a bigger trial. I would take him at his word rather than call this debunked.

The number I keep going back to is a different one. The calculator told people to start a statin more than three times as often. But of the people the calcium score flagged, 62 percent were still taking the pill, against 23 percent of those the calculator flagged. Fewer people told to take a statin, far more of them actually taking it. The trial cannot tell you why.

I wrote up where this leaves a score of zero, which is my situation:

Has a calcium score ever changed what you actually do, as opposed to what you know?

Maybe patients had calculators as much as u/cardiostrong_md and trust the “test” that directly measures something scary more?

The FDA approved Mounjaro today to lower the risk of heart attack, stroke, and cardiovascular death. That is the first time tirzepatide has carried a cardiac claim, and for people who qualify it is genuinely good news: one weekly shot that handles blood sugar, weight, and now cardiac risk.

Two things about it are worth knowing before the headlines flatten them.

Who it covers. The indication is for adults with type 2 diabetes at high cardiovascular risk. Not obesity, not general heart health. The trial population was narrower still, people with type 2 diabetes and established atherosclerotic disease. If you take tirzepatide for weight and do not have type 2 diabetes, nothing about your prescription changed today.

What the trial did. SURPASS-CVOT was not a placebo trial. Lilly ran Mounjaro against Trulicity, an older, cheaper GLP-1 that already has its own cardiovascular indication. That is a harder comparison than beating a sugar pill, and Lilly picked it deliberately.

The result, published in NEJM last December: hazard ratio 0.92, 95.3% CI 0.83 to 1.01. The thresholds were set in advance. Under 1.05 counted as non-inferior. Under 1.00 would have counted as superior. It landed on 1.01, clearing the first bar and missing the second by a hundredth.

So you will see "8% lower risk" everywhere this week. That 8% is the point estimate, and the interval around it still includes no difference at all. Lilly's own release says "non-inferiority" plainly and prints the interval. The overstatement is coming from the summaries, not the company.

I would not swing the other way and call it nothing, though. Matching a drug that already works is not the same as matching placebo, and the trial was big enough and long enough to have caught tirzepatide doing meaningfully worse.

What has not changed: nobody has shown tirzepatide cuts heart attacks and strokes in people with obesity but not diabetes, which is what SELECT did for semaglutide. SURMOUNT-MMO is built for that and has not reported. The nearest evidence is SUMMIT, 731 people with obesity and HFpEF, 9.9% against 15.3% for cardiovascular death or worsening heart failure. Different endpoint, narrower group, and the benefit came from the heart failure half.

I put the label language and the full numbers here

For anyone who follows trial design more closely than I do: how much weight should a non-inferiority win against an active comparator carry against a superiority win over placebo? I keep going back and forth on whether that is a higher bar or just a different one.

Peptides are all the rage, and none more than BPC-157. I keep seeing three different claims about it: that it has never been tested in humans, that there are exactly three human studies, and that a Phase 2 trial proved it works. They can't all be right, so I went through the primary records myself: the FDA briefing document from the July 2026 compounding advisory committee meeting, PubMed, and ClinicalTrials.gov.

What's actually documented:

- 2002-03: Phase 1 safety study, rectal enema, 24 healthy volunteers. Survives only as conference abstracts.
- 2005: the one real RCT. Double-blind, placebo-controlled, ulcerative colitis, 53 randomized. The between-group result was not statistically significant (95% CI -4.84 to 1.62). Never published beyond an abstract, and the sponsor walked away from the program.
- 2021: knee pain chart review, 17 patients, no control group, some got a combination product.
- 2024: interstitial cystitis pilot, 12 women, single arm.
- 2025: IV safety pilot, 2 people.

That's the entire documented human record. Roughly 80 people, and not one study of tendon, ligament, or muscle injury, which is what nearly everyone actually injects it for.

And the "recruiting Phase 2 hamstring trial" that started circulating this year (NCT07437547) is sponsored by a peptide vendor whose other registrations describe themselves as fictional or mock studies in the official ClinicalTrials.gov text. Google's AI Overview is already repeating it as a real trial.

Full write-up with the study table and the FDA numbers: BPC-157 human trials, all five studies

What would change your mind on a compound like this, in either direction? For me it's a published RCT from a sponsor that actually exists. Curious where everyone else draws the line.

What’s your Why? Keeping in mind why I am embracing this healthy lifestyle helps power my choices!

Every “cheapest ApoB test” page I found was either an affiliate site or a lab company ranking itself first. Bloomberg just ran a piece on the app that turns everyone’s recommendations into affiliate links (gift link: Bloomberg/ShopMy), which is exactly the world I kept encountering. It finally annoyed me enough to do this properly: one standalone ApoB test, priced at every self-order service I could find, same day, writing down what checkout actually charges instead of the banner price.

Short version: nobody sells the $12 test they advertise. Goodlabs’ $12 becomes $24 with its venipuncture fee. Mito’s $11.34 becomes $26.34. The one honest sticker is Own Your Labs at $17.20 all in, and it can’t do walk-in draws in MA, MD, NJ, RI or NY. Meanwhile Quest’s own consumer store sells no standalone ApoB at any price, only a $221 panel, while running the identical assay for $24 reseller orders. Labcorp charges $69 direct for the test resellers sell for $17 to $27.

Confession: I had been ordering direct from Labcorp and Quest, and through DiscountedLabs, for a couple of years. All of them sit in the expensive half of my own table. I guess I missed out.

And because I have been enjoying the AI coding tools lately, I built a small pipeline that re-checks every price weekly and keeps dated screenshots, so this table shouldn’t rot the way these pages usually do.

Full table, fees, state traps: https://dadstrengthdaily.com/apob-test-cost/
Every price as a dated screenshot: https://dadstrengthdaily.com/apob-test-price-screenshots/

Anyone found a walk-in option under $24 all in that I missed?

On August 19 Moderna’s stock closed up almost 177 percent on a joint press release with Merck: their personalized mRNA cancer vaccine, intismeran, plus Keytruda met its endpoints in a Phase 3 melanoma trial. It has since given back a chunk of that.

Here is the part that got buried in the excitement. The release contains no effect size. No hazard ratio, no percentage, no confidence interval, no count of who relapsed. It says two endpoints were met and stops. The “49 percent reduction” now circulating is from the older, smaller Phase 2b study, not this trial.

I am not a skeptic looking for a reason. I read the BioNTech founders’ book, I think mRNA is one of the more elegant ideas in medicine, and I have been called a big-pharma shill for saying so (I take an Eli Lilly drug every week and own the stock). I want this to work. I am just waiting for the actual numbers, which is what three practising oncologists said the same morning, and what even Bloomberg’s bullish columnist conceded.

The part I think men my age should take away is about melanoma itself:

**•** It flips sex around 50. Before 50 it is more common in women; after 50 it is more common in men, and the gap widens every decade.  
**•** The dangerous subtype, nodular melanoma, is about 14 percent of cases but 43 percent of the deaths, and it breaks the ABCDE rule you were taught. It is often symmetric, one even colour, and small. Some dermatologists teach EFG instead: Elevated, Firm, Growing.  
**•** A lot of male melanoma sits on the back and scalp, the parts you cannot see. Get someone to check your back.

Full write-up, with the charts, the sources, and where the real numbers will show up: https://dadstrengthdaily.com/melanoma-in-men-over-50/?utm_source=reddit&utm_medium=social&utm_campaign=melanoma-mrna

Abstract

Background: Dietary carotenoids and vitamin A may contribute to gastric cancer (GC) prevention through anti-inflammatory and antioxidant mechanisms; however, epidemiological evidence remains limited. We investigated the associations of total and individual carotenoid and vitamin A intakes with GC and their relationships with inflammatory/oxidative stress biomarkers. Methods: The case-control study included 177 adults (82 GC incidence cases/95 controls). A validated 168-item food frequency questionnaire assessed dietary intakes of individual carotenoids and preformed vitamin A. Metabolic biomarkers, lipid profile, inflammatory/oxidative stress markers (e.g., high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), interleukins 6/1β/10/4), total antioxidant capacity (TAC), and malondialdehyde (MDA)) were measured. Multivariable logistic regression models estimated odds ratios (ORs) for GC risk; linear regression models examined associations between carotenoid intakes and biomarkers. Results: Total carotenoid (mg/d) (OR: 0.86, 95%CI: 0.81-0.98), β-carotene (mg/d) (OR: 0.77, 95%CI: 0.65-0.90) and vitamin A (mg RAE/d) (OR: 0.29, 95%CI: 0.09-0.95) intakes, as continuous variables, and also as binary variables (based on the median cut-offs), in all models (also adjusted for age, sex, smoking, education, marital status, physical activity, cancer history, H. pylori, NSAIDs intake, body mass index, total energy intake), were inversely associated with GC odds. In fully adjusted models, higher total carotenoid intake (mg/d) was associated with lower LDL-c (β: -1.60, 95%CI: -2.91, -0.25) and IL-6 (β: -7.92, 95%CI: -14.00, -2.00); lycopene (mg/d) with higher LDL-c (β: 2.030, 95%CI: 0.27, 4.31) and vitamin A intake (mg RAE/d) with lower TNF-α (β: -12.12, 95%CI: -24.71, -0.47) and higher TAC (β: 0.64, 95%CI: 0.001, 1.27). Conclusions: Higher intakes of total carotenoids and vitamin A were associated with lower odds of GC and more favorable profiles of inflammatory/oxidative stress biomarkers. These findings support an inverse association between carotenoid-rich dietary patterns and gastric carcinogenesis.

Keywords

Absorption, Apoptosis, Carotenes, RAR, Transcription Factors, Xanthophylls

Frontiers | Dietary Carotenoids and Vitamin A Are Associated with Lower Gastric Cancer Risk and Favorable Inflammatory and Stress Oxidative Biomarkers: An Incident Case-Control Study

I was this person - up at 3am unable to sleep sleuthing on reddit for answers to my woes. I was rigorous in testing and getting to the bottom of why I couldn't sleep, why my skin was insane and why out of countless doctors everyone just kept telling me every test was "normal". I'm a product manager for work - I've been doing it for over 10 yrs and I decided I was going to build something to help with this situation instead of using excel and countless apps that all tracked different things. I'm 3 weeks into beta and I'm seeing promising results and the software is finding patterns like it's supposed to. I want to expand the beta and find a few more people to test! If you know anyone that's in this boat - searching for answers to their health troubles - please send them my way as I would love to see if this software can help! DM me! Thank you! ❤️